source
- Xaira Therapeutics details its generative AI antibody platform X-Design and unveils first pipeline candidatesXaira Therapeutics, which raised $1 billion in 2024, has now shared details of its AI-driven antibody design platform called X-Design and provided a glimpse of its emerging pipeline. The company s…
- Sarepta's Elevidys shows durable benefit in ambulatory Duchenne patients, analysts see turnaround potentialJefferies analysts said Sarepta Therapeutics could become a turnaround story after the company presented new data on its Duchenne muscular dystrophy gene therapy Elevidys. The late-breaking poster…